LimaCorporate Gets US FDA Nod To Begin Clinical Trial Of SMR Stemless Reverse Shoulder System

LimaCorporate, a global medical device company, announced that the US Food and Drug Administration (FDA) has approved the Investigational Device Exemption (IDE) to start the clinical trial of the SMR Stemless Reverse Shoulder System.The US FDA approval allows LimaCorporate to start a randomized, multi-center comparative clinical trial on the SMR Stemless Reverse in the US to evaluate its safety and effectiveness compared to the SMR Reverse Shoulder System, in total reverse shoulder arthroplasty. The trial will enroll 200 patients with a two-year follow-up and is planned to start in Q1 2021 with seven US investigational sites involved. SMR Stemless Reverse system has been approved in Europe, Mexico and selected APAC markets including Australia, New Zealand and South Korea.SMR Stemless Reverse, part of the SMR System, is an innovative bone sparing shoulder arthroplasty implant indicated for the treatment of patients with a grossly deficient rotator cuff, with the advantage of preserving humeral bone, allowing smoother revision procedures, and preventing stem-related complications.SMR Stemless Reverse Shoulder System is compatible with the previously US FDA cleared SMR Reverse Shoulder components currently on the market since 2011. The Stemless Core features Trabecular Titanium (TT), LimaCorporate's 3D printed leading technology, and a reverse liner on the humeral side. On the glenoid side, the polyethylene glenosphere represents an innovative solution in reverse shoulder arthroplasty because the inversion of the materials avoids the scapular notching phenomenon, frequently associated with this type of surgery.Luigi Ferrari, CEO of LimaCorporate, commented, "We are very excited about the approval of the IDE study for the SMR Stemless Reverse. It is a major and strategic achievement for LimaCorporate, allowing us to start a clinical trial on a device that addresses the needs of reverse shoulder arthroplasty in the US market. The IDE study demonstrates LimaCorporate's focus on improving patients' lives through constant research and innovation, empowering and assisting surgeons to restore the emotion of motion in their patients."Michael Bauer, partner at EQT and co-head of EQT's Healthcare Sector Team, added, "The IDE approval is a major milestone as LimaCorporate remains committed to providing surgeons innovative solutions while upholding the highest clinical standards to ensure patient safety and implant effectiveness

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!